Literature DB >> 6209222

Mouse monoclonal antibodies reactive with J5 lipopolysaccharide exhibit extensive serological cross-reactivity with a variety of gram-negative bacteria.

M J Nelles, C A Niswander.   

Abstract

We describe two mouse monoclonal antibodies reactive with lipopolysaccharide derived from the J5 mutant of Escherichia coli O111:B4. These antibodies react with purified lipopolysaccharide derived from rough mutants of E. coli and Salmonella typhimurium and also with lipopolysaccharide associated with both smooth- and rough-phenotype, gram-negative bacteria. Both antibodies appear to bind determinants present in the lipopolysaccharide core region, and this reactivity is inhibited in the presence of polymyxin B. Although their patterns of reactivity differ, both antibodies exhibit extensive serological cross-reactivity with a variety of gram-negative bacteria. Reagents of this type should prove useful in animal models to delineate the requisite affinity, epitope specificity, immunoglobulin class, etc., needed for the prevention and treatment of gram-negative bacteremia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6209222      PMCID: PMC261596          DOI: 10.1128/iai.46.3.677-681.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides.

Authors:  D C Morrison; D M Jacobs
Journal:  Immunochemistry       Date:  1976-10

2.  Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.

Authors:  E J Ziegler; H Douglas; J E Sherman; C E Davis; A I Braude
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

3.  Standardization of the chloramine-T method of protein iodination.

Authors:  R Hunter
Journal:  Proc Soc Exp Biol Med       Date:  1970-03

Review 4.  Immunochemistry of O and R antigens of Salmonella and related Enterobacteriaceae.

Authors:  O Lüderitz; A M Staub; O Westphal
Journal:  Bacteriol Rev       Date:  1966-03

5.  A new method for the extraction of R lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1969-06

6.  Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1971-12-22

7.  Immunization with R mutants of Salmonella minnesota. II. Comparison of the protective effect of immunization with lipid A and the Re mutant.

Authors:  S C Bruins; R Stumacher; M A Johns; W R McCabe
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

8.  Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia.

Authors:  A I Braude; E J Ziegler; H Douglas; J A McCutchan
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

Review 9.  Cross-reactive antigens: their potential for immunization-induced immunity to Gram-negative bacteria.

Authors:  W R McCabe; S C Bruins; D E Craven; M Johns
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

10.  Immunization with R mutants of Salmonella minnesota. II. Serological response to lipid A and the lipopolysaccharide of Re mutants.

Authors:  M A Johns; S C Bruins; W R McCabe
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

View more
  17 in total

Review 1.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

Review 2.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

3.  A murine monoclonal antibody specific for the outer core oligosaccharide of Salmonella lipopolysaccharide.

Authors:  R S Tsang; K H Chan; P Y Chau; K C Wan; M H Ng; S Schlecht
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

4.  Cross-reactivity of monoclonal antibodies against lipopolysaccharides of gram-negative bacteria.

Authors:  J de Jongh-Leuvenink; A S Bouter; J H Marcelis; J Schellekens; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

Review 5.  Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.

Authors:  D L Dunn
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

6.  A direct enzyme-linked immunosorbent assay (ELISA) for antibodies to enterobacterial Re core glycolipid and lipid A. Results in healthy subjects and in patients infected by gram-negative bacteria.

Authors:  M Nys; P Damas; F Damas; L Joassin; J Demonty
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

7.  Characterization of anti-core glycolipid monoclonal antibodies with chemically defined lipopolysaccharides.

Authors:  J de Jongh-Leuvenink; J Schellekens; J Verhoef
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

8.  Mechanisms involved in protection provided by immunization against core lipopolysaccharides of Escherichia coli J5 from lethal Haemophilus pleuropneumoniae infections in swine.

Authors:  B W Fenwick; J S Cullor; B I Osburn; H J Olander
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

9.  Complement activating and opsonic capacity of monoclonal antibodies raised against Escherichia coli O111 and its rough mutant J5.

Authors:  R W Vreede; J Leuvenink; A S Bouter; E C Brouwer; J H Marcelis; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

10.  A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides.

Authors:  F E Di Padova; H Brade; G R Barclay; I R Poxton; E Liehl; E Schuetze; H P Kocher; G Ramsay; M H Schreier; D B McClelland
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.